MAIA Biotechnology (MAIA) Net Cash Flow (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Net Cash Flow for 6 consecutive years, with -$6.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 837.23% year-over-year to -$6.8 million in Q2 2026; TTM through Jun 2026 was $17.5 million, a 1321.72% increase from a year earlier, with the FY2025 full-year figure at -$938051.0, down 137.94% from the prior year.
• Net Cash Flow was -$6.8 million for Q2 2026 at MAIA Biotechnology, down from $25.7 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $25.7 million in Q1 2026 and troughed at -$6.8 million in Q2 2026.
• A 5-year average of $717859.1 and a median of -$501848.5 in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow tumbled 1115.2% in 2023 and jumped 1944.65% in 2026, its largest moves.
• Over 5 years, Net Cash Flow stood at -$3.1 million in 2022, then surged by 132.87% to $1.0 million in 2023, then retreated by 9.26% to $937288.0 in 2024, then tumbled by 336.65% to -$2.2 million in 2025, then slumped by 207.25% to -$6.8 million in 2026.
• The last three Net Cash Flow figures came in at -$6.8 million (Q2 2026), $25.7 million (Q1 2026), and -$2.2 million (Q4 2025), per Business Quant data.